Patents by Inventor Samson FUNG

Samson FUNG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD70 COMBINATION THERAPY
    Publication number: 20240033353
    Abstract: The present invention provides combinations and methods using same for the treatment of malignancy, particularly a myeloid malignancy such as acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), chronic myeloid leukemia (CML), and chronic myelomonocytic leukemia (CMML). The combination may comprise an antibody or antigen-binding fragment thereof that binds to CD70, and an inhibitor of BCL-2. In certain embodiments, the antibody is ARGX-110 (cusatuzumab). In certain embodiments, the BCL-2 inhibitor is venetoclax. In certain embodiments, the combination provides synergistic treatment of AML. The combination may additionally comprise at least one additional anti-cancer agent.
    Type: Application
    Filed: June 14, 2023
    Publication date: February 1, 2024
    Inventors: Johannes DE HAARD, Samson FUNG, Nicolas LEUPIN, Adrian OCHSENBEIN, Carsten RIETHER, Luc VAN ROMPAEY
  • CD70 combination therapy
    Patent number: 11712468
    Abstract: The present invention provides combinations and methods using same for the treatment of malignancy, particularly a myeloid malignancy such as acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), chronic myeloid leukemia (CML), and chronic myelomonocytic leukemia (CMML). The combination may comprise an antibody or antigen-binding fragment thereof that binds to CD70, and an inhibitor of BCL-2. In certain embodiments, the antibody is ARGX-110 (cusatuzumab). In certain embodiments, the BCL-2 inhibitor is venetoclax. In certain embodiments, the combination provides synergistic treatment of AML. The combination may additionally comprise at least one additional anti-cancer agent.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: August 1, 2023
    Assignees: ARGENX BV, University of Bern
    Inventors: Johannes De Haard, Samson Fung, Nicolas Leupin, Adrian Ochsenbein, Carsten Riether, Luc Van Rompaey
  • CD70 COMBINATION THERAPY
    Publication number: 20200222532
    Abstract: The present invention provides combinations and methods using same for the treatment of malignancy, particularly a myeloid malignancy such as acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), chronic myeloid leukemia (CML), and chronic myelomonocytic leukemia (CMML). The combination may comprise an antibody or antigen-binding fragment thereof that binds to CD70, and an inhibitor of BCL-2. In certain embodiments, the antibody is ARGX-110 (cusatuzumab). In certain embodiments, the BCL-2 inhibitor is venetoclax. In certain embodiments, the combination provides synergistic treatment of AML. The combination may additionally comprise at least one additional anti-cancer agent.
    Type: Application
    Filed: December 18, 2019
    Publication date: July 16, 2020
    Inventors: Johannes DE HAARD, Samson FUNG, Nicolas LEUPIN, Adrian OCHSENBEIN, Carsten RIETHER, Luc VAN ROMPAEY